Nexalin Technology (NXL) EBITDA Margin Growth (1y) (2022 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -430.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 128.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -361.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 141.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 102.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 58.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 851.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -313.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 535.00 |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | -917,927.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -917,927.00 |
| Dec 31, 2025 | 904,324.00 |
| Sep 30, 2025 | -575,463.00 |
| Jun 30, 2025 | 254,582.00 |
| Mar 31, 2025 | -352,258.00 |
| Dec 31, 2024 | -661,786.00 |
| Sep 30, 2024 | 286,491.00 |
| Jun 30, 2024 | -244,826.00 |
| Mar 31, 2024 | 99,138.00 |
| Dec 31, 2023 | -200,283.00 |
| Sep 30, 2023 | -963,584.00 |
| Jun 30, 2023 | -222,496.00 |
| Mar 31, 2023 | -219,298.00 |
| Dec 31, 2022 | 60,180.00 |
| Sep 30, 2022 | 318,305.00 |